Levofloxacin-loaded nanoparticles decrease emergence of fluoroquinolone resistance in Escherichia coli

Microbial Drug Resistance

Volumn 24, Issue 8, 2018, Pages 1098-1107

  Hadiya, Safy ^a   Liu, Xiaoqiang ^b   Abd El Hammed, Wegdan ^c   Elsabahy, Mahmoud ^a,d,e,f   Aly, Sherine A ^c  

^a ASSIUT UNIVERSITY   (Egypt)

^b NORTHWEST A F UNIVERSITY   (China)

^c Assiut University Faculty of Medicine   (Egypt)

^d Assiut University   (Egypt)

^e TEXAS A AND M UNIVERSITY   (United States)

^f MISR UNIVERSITY FOR SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

antimicrobial resistance; genetic mutations; levofloxacin; nanoparticles

Indexed keywords

CHITOSAN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; LEVOFLOXACIN; NANOPARTICLE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; BROTH DILUTION; CROSS RESISTANCE; DISPERSITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; ENCAPSULATION; ESCHERICHIA COLI; FREEZE DRYING; GENE MUTATION; HYDRODYNAMICS; IN VITRO SELECTION; IN VITRO STUDY; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MORPHOLOGICAL TRAIT; MUTATION RATE; NANOENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATOR GENE; SHELF LIFE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; DRUG EFFECT; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION; PROCEDURES;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MUTATION; NANOPARTICLES;

EID: 85049407722     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2017.0304     Document Type: Article

References (32)

1. Wispelwey, B., K.R. Schafer. 2010. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Rev. Anti Infect. Ther. 8:1259-1271.
2. Liu, X., C. Lazzaroni, S.A. Aly, K. Thungrat, and D.M. Boothe. 2014. In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates. Vet. Microbiol. 174:514-522.
3. Piddock, L.J. 1995. Mechanisms of resistance to fluoroquinolones: State-of-the-art 1992-1994. Drugs 49:29-35.
4. Duval, V., I.M. Lister. 2013. MarA, SoxS and Rob of Escherichia coli-global regulators of multidrug resistance, virulence and stress response. Int. J. Biotechnol. Wellness Ind. 2:101-124.
5. Hirai, K., H. Aoyama, T. Irikura, S. Iyobe, and S. Mitsuhashi. 1986. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob. Agents Chemother. 29:535-538.
6. Moniot-Ville, N., J. Guibert, N. Moreau, J. Acar, E. Collatz, and L. Gutmann. 1991. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob. Agents Chemother. 35:519-523.
7. Armentano, I., C.R. Arciola, E. Fortunati, D. Ferrari, S. Mattioli, C.F. Amoroso, J. Rizzo, J.M. Kenny, M. Imbriani, and L. Visai. 2014. The interaction of bacteria with engineered nanostructured polymeric materials: A review. ScientificWorldJounal 2014:1-19.
8. Lim, Y.H., K.M. Tiemann, D.A. Hunstad, M. Elsabahy, and K.L. Wooley. 2016. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8: 842-871.
9. Mekkawy, A.I., M.A. El-Mokhtar, N.A. Nafady, N. Yousef, M.A. Hamad, S.M. El-Shanawany, E.H. Ibrahim, and M. Elsabahy. 2017. In vitro and in vivo evaluation of biologically synthesized silver nanoparticles for topical applications: Effect of surface coating and loading into hydrogels. Int. J. Nanomedicine 12:759-777.
10. Abdelkader, A., M.A. El-Mokhtar, O. Abdelkader, M.A. Hamad, M. Elsabahy, and O.N. El-Gazayerly. 2017. Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model. Carbohydr. Polym. 174:1041-1050.
11. Siafaka, P.I., A.P. Zisi, M.K. Exindari, I.D. Karantas, and D.N. Bikiaris. 2016. Porous dressings of modified chitosan with poly(2-hydroxyethyl acrylate) for topical wound delivery of levofloxacin. Carbohydr. Polym. 143:90-99.
12. Guan, J., P. Cheng, S. Huang, J. Wu, Z. Li, X. You, L. Hao, Y. Guo, R. Li, and H. Zhang. 2011. Optimized preparation of levofloxacin-loaded chitosan nanoparticles by ionotropic gelation. Physics Procedia. 22:163-169.
13. Katas, H., M.A.G. Raja, and K.L. Lam. 2013. Development of chitosan nanoparticles as a stable drug delivery system for protein/siRNA. Int. J. Biomater. 2013:1-10.
14. Elzeny, H., F. Zhang, E.N. Ali, H.A. Fathi, S. Zhang, R. Li, M.A. El-Mokhtar, M.A. Hamad, K.L. Wooley, and M. Elsabahy. 2017. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA. Drug Des. Dev. Ther. 11:483-496.
15. Morsi, N.G., S.M. Ali, S.S. Elsonbaty, A.A. Afifi, M.A. Hamad, H. Gao, and M. Elsabahy. 2017. Poly (glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA. Pharm. Dev. Technol. 7:1-13.
16. Lyu LaZ, G. 2014. Determination of rifampicin-resistance mutation frequency and analysis of mutation spectra in mycobacteria. Bio-protocol 4:1-6.
17. Boothe, D.M., H.W. Boothe, Jr. 2015. Antimicrobial considerations in the perioperative patient. Vet. Clin. North Am. Small Anim. Pract. 45:585-608.
18. Yamagishi, J., Y. Sato, N. Shinozaki, B. Ye, A. Tsuboi, M. Nagasaki, and R. Yamashita. 2016. Comparison of boiling and robotics automation method in DNA extraction for metagenomic sequencing of human oral microbes. PLoS One 11:1-15.
19. Boyd, L.B., M.J. Maynard, S.K. Morgan-Linnell, L.B. Horton, R. Sucgang, R.J. Hamill, J.R. Jimenez, J. Versalovic, D. Steffen, and L. Zechiedrich. 2009. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53: 229-234.
20. Morones, J.R., J.L. Elechiguerra, A. Camacho, K. Holt, J.B. Kouri, J.T. Ram?rez, and M.J. Yacaman. 2005. The bactericidal effect of silver nanoparticles. Nanotechnology 16: 2346-2353.
21. Mu, H., J. Tang, Q. Liu, C. Sun, T. Wang, and J. Duan. 2016. Potent antibacterial nanoparticles against biofilm and intracellular bacteria. Sci. Rep. 6:1-9.
22. Fei Liu, X., Y. Lin Guan, D. Zhi Yang, Z. Li, and K. De Yao. 2001. Antibacterial action of chitosan and carboxymethylated chitosan. J. Appl. Polym. Sci. 79:1324-1335.
23. Feris, K., C. Otto, J. Tinker, D. Wingett, A. Punnoose, A. Thurber, M. Kongara, M. Sabetian, B. Quinn, and C. Hanna. 2009. Electrostatic interactions affect nanoparticlemediated toxicity to gram-negative bacterium Pseudomonas aeruginosa PAO1. Langmuir 26:4429-4436.
24. Raja, M.A.G., H. Katas, and T.J. Wen. 2015. Stability, intracellular delivery, and release of siRNA from chitosan nanoparticles using different cross-linkers. PLoS One 10:1-19.
25. Capita, R., C. Alonso-Calleja. 2013. Antibioticresistant bacteria: A challenge for the food industry. Crit. Rev. Food Sci. Nutr. 53:11-48.
26. Salouti, M., A. Ahangari. 2014. Nanoparticle based drug delivery systems for treatment of infectious diseases. Appl. Nanotechnol. Drug Deliv. 156:1-39.
27. Lee, C.-R., I.H. Cho, B.C. Jeong, and S.H. Lee. 2013. Strategies to minimize antibiotic resistance. Int. J. Environ. Res. Public Health 10:4274-4305.
28. Aly, S.A., N. Debavalya, S.-J. Suh, O.A. Oryazabal, and D.M. Boothe. 2012. Molecular mechanisms of antimicrobial resistance in fecal Escherichia coli of healthy dogs after enrofloxacin or amoxicillin administration. Can. J. Microbiol. 58:1288-1294.
29. Aly, S.A, D.M. Boothe, and S.J. Suh. 2015. A novel alanine to serine substitution mutation in SoxS induces overexpression of efflux pumps and contributes to multidrug resistance in clinical Escherichia coli isolates. J. Antimicrob. Chemother. 70:2228-2233.
30. Karczmarczyk, M., M. Martins, T. Quinn, N. Leonard, and S. Fanning. 2011. Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals. Appl. Environ. Microbiol. 77:7113-7120.
31. Koutsolioutsou, A., S. Penã-Llopis, and B. Demple. 2005. Constitutive soxR mutations contribute to multipleantibiotic resistance in clinical Escherichia coli isolates. Antimicrob. Agents Chemother. 49:2746-2752.
32. Aldred, K.J., R.J. Kerns, and N. Osheroff. 2014. Mechanism of quinolone action and resistance. Biochemistry 53: 1565-1574.